Gabriel Salinas Cisneros

Gabriel Salinas Cisneros

Auto-generated profile, based on publicly available information

Gabriel Salinas Cisneros

Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in HemaSphere
Verified
Journal Article
Open access
GCGabriel Salinas Cisneros
Gabriel Salinas Cisneros
STSwee Lay Thein
Swee Lay Thein
Sickle cell disease (SCD) is an exemplar of bidirectional translational research, starting with a remarkable astute observation of the abnormally shaped red blood cells that motivated decades of bench research that have now translated into new drugs and genetic therapies. Introduction of hydroxyurea (HU) therapy, the only SCD-modifying treatment for >30 years and now standard care, was initiated through another clinical observation by a pediatrician. While the clinical efficacy of HU is primarily due to its fetal hemoglobin (HbF) induction, the exact mechanism of how it increases HbF remains not fully understood. Unraveling of the molecular mechanism of how HU increases HbF has provided insights on the development of new HbF-reactivating agents in the pipeline. HU has other salutary effects, reduction of cellular adhesion to the vascular endothelium and inflammation, and dissecting these mechanisms has informed bench—both cellular and animal—research for development of the 3 recently approved agents: endari, voxelotor, and crizanlizumab; truly, a bidirectional bench to bedside translation. Decades of research to understand the mechanisms of fetal to adult hemoglobin have also culminated in promising anti-sickling genetic therapies and the first-in-human studies of reactivating an endogenous (γ-globin) gene HBG utilizing innovative genomic approaches.

10 February 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CDChristopher C. Dvorak
Christopher C. Dvorak
WTWilliam C. Temple
William C. Temple
GCGabriel Salinas Cisneros
Gabriel Salinas Cisneros
JCJulia Chu
Julia Chu
LWLena E. Winestone
Lena E. Winestone
JLJanel R. Long-Boyle
Janel R. Long-Boyle
Successful allogeneic hematopoietic cell transplantation (HCT) for genetic non-malignant diseases (NMD) is dependent upon elimination of host hematopoietic stem cells (HSCs) and replacement with donor HSCs in stable numbers sufficient to correct the underlying disease. Donor myeloid chimerism (DMC) in peripheral blood (PB) is a surrogate marker for bone marrow HSC engraftment due to the rapid turnover of PB myeloid cells. Busulfan is commonly used during conditioning for patients with NMD, though its optimal exposure to avoid inadequate DMC is not fully known. Younger patients with NMD have more mixed chimerism compared to older patients when receiving melphalan-based conditioning, possibly due to increased marrow reserve; we hypothesized that a similar phenomenon would occur with busulfan-based conditioning. We performed a retrospective analysis of 105 consecutive patients with NMDs (median age of 3.9 years) undergoing first allogeneic HCT with myeloablative (cAUC ≥55 mg*hr/L) busulfan-based conditioning from 2007-2023 and evaluated risk factors for the development of mixed (<95%) and minimal (≤20%) DMC. Receiver operating curve analysis demonstrated that age <2.9 years was the cut-off associated with mixed DMC. The cohort was therefore divided into two age groups: <3 years (43.8% of patients) and ≥3 years; there was no difference in busulfan exposure between the groups. The 3-year cumulative incidence of developing mixed DMC was 20.3% (95% CI, 12.1-28.5%). Age was associated with mixed DMC by 3 years post-HCT: 45.2% (95% CI, 29.7-60.7%) in those <3 years versus 1.9% (95% CI, 0.1-5.4%) in those ≥3 years (p<0.001). Busulfan exposure was also associated with mixed DMC: 24.8% (95% CI, 14.8-34.8%) in those with cAUC 55-74.9 mg*hr/L versus 5% (95% CI, 0.1-8.3%) in those with cAUC ≥75 mg*hr/L (p=0.03). In patients ≥3 years of age, there was no impact of busulfan exposure on development of mixed DMC. The 3-year cumulative incidence of developing minimal DMC was 5.5% (95% CI, 0.8-10.2%). Only young age was significantly associated with minimal DMC by 3 years post-HCT: 12.8% (95% CI, 2.2-23.4%) in those <3 years versus 0% (95% CI, 0-6.1%) in those ≥3 years (p=0.008). There was no impact of age or busulfan exposure on immunologic graft rejection, acute or chronic graft-versus-host-disease, or transplant-related mortality. There was no difference in sinusoidal obstruction syndrome (SOS) incidence based on busulfan exposure: 13.7% (95% CI, 6.3-21.1%) for a cAUC of 55-74.9 mg*hr/L compared to 20.8% (95% CI, 4.5-37.1%) for a cAUC of ≥75 mg*hr/L (p=0.33). However, the incidence of SOS was impacted by patient age: 32.9% (95% CI, 19.2-46.6%) in patients <3 years compared to 1.7% (95% CI, 0.1-5%) in patients ≥3 years (p<0.001). Age <3 years at time of HCT is the major risk factor for mixed and minimal DMC in patients with NMD who receive busulfan-based conditioning. Patients ≥3 years of age may not require busulfan exposures above 55-60 mg*hr/L to develop full DMC. Conversely, to avoid development of mixed DMC, patients <3 years may benefit from either HCT delay (when feasible) or higher (≥75 mg*hr/L) busulfan exposure, albeit carrying a high-risk for SOS development.

4 April 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CDChristopher C. Dvorak
Christopher C. Dvorak
SCSoohee Cho
Soohee Cho
GCGabriel Salinas Cisneros
Gabriel Salinas Cisneros
CHChristine S. Higham
Christine S. Higham
JCJulia Chu
Julia Chu
JLJanel R. Long-Boyle
Janel R. Long-Boyle
Melphalan is often used as the backbone agent for conditioning prior to A/B-T-cell depleted (A/B-TCD) hematopoietic cell transplant (HCT) due to lower rates of organ toxicity compared to busulfan or total-body irradiation, albeit with significant mucosal injury. Traditional dosing based on body-surface-area (BSA) may result in non-optimal melphalan exposure among certain patient subsets. As mucosal injury is linked to initiation of alloreactivity, we hypothesized that high exposure of melphalan predicted via a pharmacokinetic (PK) model would be associated with an increased risk of acute graft-versus-host disease (aGVHD). We performed an analysis of 85 patients who underwent A/B-TCD haploidentical HCT on two prospective trials using melphalan-based conditioning for treatment of malignancy at three centers from 2015-2024. Most patients (61.2%) received a total dose of melphalan at 140 mg/m2 using actual body weight; others received a dose adjusted for obesity or age <2 years. We analyzed outcomes based on whether melphalan exposure was above or below the median exposure for the group. The 100-day cumulative incidences of engraftment syndrome (ES), grade II-IV aGVHD, and grade III-IV aGVHD were 34.2%, 24.8%, and 17.1%, respectively. The 3-year cumulative incidence of chronic GVHD (cGVHD), non-relapse mortality (NRM), and relapse were 17.5%, 8.7%, 21.8%, respectively. The 3-year cumulative incidence of disease-free survival (DFS) and severe GVHD-relapse-free survival (GRFS) were 71.4% and 55.6%, respectively. ES was significantly associated with the subsequent development of aGVHD, both grade II-IV (41.4% vs. 17.3% in those with and without ES, p=0.01) and grade III-IV (34.5% vs. 8.5% in those with and without ES; p=0.003). Chronic GVHD occurred at significantly higher rates in patients with prior Grade II-IV (66.7% vs. 0% for Grade 0-I; p<0.001) and Grade III-IV aGVHD (75% vs. 4.3% for Grade 0-II; p6.8 mg*hr/L was associated with a higher incidence of ES (48.8% vs. 19.1%; p=0.005), grade II-IV aGVHD (39.3% vs. 10.1%; p=0.002), and grade III-IV aGVHD (31.5% vs. 2.5%; p<0.001). The 3-year incidence of cGVHD was 27.2% in those with high predicted melphalan exposure compared to 7.4% for low exposure (p=0.03); with no difference in 3-year NRM incidence (9.2% vs. 7.7%; p=0.82) or 3-year relapse incidence (16.8% vs. 27.6%; p=0.31) for high compared to low exposure. However, GRFS was significantly worse in patients with high exposure (46.4%) vs. low exposure (64.6%; p=0.02). High melphalan exposure predicted by a validated population PK model is associated with an increased likelihood of developing ES and subsequently acute and chronic GVHD. Given that a substantial number of patients already require adjustment of standard BSA-based dosing for young age or obesity, a prospective trial of model-based dosing to individualize melphalan exposure is warranted to confirm these results.

16 April 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GCGabriel Salinas Cisneros
Gabriel Salinas Cisneros
CDChristopher C. Dvorak
Christopher C. Dvorak
JLJanel Long-Boyle
Janel Long-Boyle
SKSandhya Kharbanda
Sandhya Kharbanda
KSKristin A. Shimano
Kristin A. Shimano
CHChristine S. Higham
Christine S. Higham
Sinusoidal obstructive syndrome (SOS), or veno-occlusive disease (VOD), of the liver has been recognized as a complex, life-threatening complication in the post-hematopoietic stem cell transplant (HSCT) setting. The diagnostic criteria for SOS have evolved over the last several decades with a greater understanding of the underlying pathophysiology, with two recent diagnostic criteria introduced in 2018 (EBMT criteria) and 2020 (Cairo criteria). We sought out to evaluate the performance characteristics in diagnosing and grading SOS in pediatric patients of the four different diagnostic criteria (Baltimore, Modified Seattle, EBMT, and Cairo) and severity grading systems (defined by the EBMT and Cairo criteria). Design: Retrospective chart review of children, adolescent and young adults (CAYA) who underwent conditioned autologous and allogeneic HSCT between 2017 and 2021 at a single pediatric institution. A total of 250 consecutive patients underwent at least one HSCT at UCSF Benioff Children's Hospital San Francisco for a total of 307 HSCT. The day 100 cumulative incidence of SOS was 12.1%, 21.1%, 28.4%, and 28.4% per the Baltimore, Modified Seattle, EBMT, and Cairo criteria, respectively (p<0.001). We found that patients diagnosed with grade ≥4 SOS per the Cairo criteria were more likely to be admitted to the PICU (92% vs. 58%, p=0.035) and intubated (85% vs. 32%, p=0.002) than those diagnosed with grade ≥4 per EBMT criteria. Age <3 years-old (HR 1.76, 95% [1.04-2.98], p=0.036), an abnormal BMI (HR 1.69, 95% [1.06-2.68], p=0.027), and high-risk patients per our institutional guidelines (HR 1.68, 95% [1.02-2.76], p=0.041) were significantly associated with SOS per the Cairo criteria. We demonstrate that age <3 years, abnormal BMI, and other high-risk criteria associate strongly with subsequent SOS development. Patients with moderate to severe SOS based on Cairo severity grading criteria may correlate better with clinical course based on ICU admissions and intubations when compared to the EBMT severity grading system.

15 November 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
ZHZahra Hudda
Zahra Hudda
AWAaron Webster
Aaron Webster
EAEric Anderson
Eric Anderson
PBPriscila Badia
Priscila Badia
RBRochelle Bagatell
Rochelle Bagatell
CDChristopher E Dandoy
Christopher E Dandoy

12 July 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
GCGabriel Salinas Cisneros
Gabriel Salinas Cisneros
JWJennifer Webb
Jennifer Webb
NLNaomi L. C. Luban
Naomi L. C. Luban
RNRobert Sheppard Nickel
Robert Sheppard Nickel